Development of resistance to chloroquine by Plasmodium vivax in Myanmar
- 1 May 1995
- journal article
- Published by Oxford University Press (OUP) in Transactions of the Royal Society of Tropical Medicine and Hygiene
- Vol. 89 (3), 307-308
- https://doi.org/10.1016/0035-9203(95)90556-1
Abstract
Fifty patients with Plasmodium vivax infection were treated with the standard regimen of chloroquine phosphate (1500 mg over 3 d) followed by primaquine (45 mg immediately and then weekly for 8 weeks); 43 patients had sensitive infections but recrudescences of parasitaemia occurred between days 3 and 14 with RI, RII and RIII patterns in one, 3 and 3 patients, respectively. All the chloroquine-resistant cases were again treated with chloroquine (1500 mg) and no further recrudescence or relapse was detected on days 21 and 28. This study indicates that chloroquine is losing its efficacy against P. vivax in Myanmar.Keywords
This publication has 6 references indexed in Scilit:
- Chloroquine-resistant Plasmodium vivax in Papua New GuineaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1992
- Chloroquine-ResistantPlasmodium vivaxfrom IndonesiaNew England Journal of Medicine, 1991
- PLASMODIUM VIVAX RESISTANCE TO CHLOROQUINE?The Lancet, 1989
- Electrophoretic variants of enzymes in isolates of Plasmodium falciparum, P. malariae and P. vivax from ThailandTransactions of the Royal Society of Tropical Medicine and Hygiene, 1989
- Plasmodium vivax: enzyme polymorphism in isolates of Indian originTransactions of the Royal Society of Tropical Medicine and Hygiene, 1989
- Isoenzyme variation in schizonts of Plasmodium vivax from BurmaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1986